Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2011Open Access

Treatment of von Willebrand disease with FVIII/VWF concentrates.

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with von Willebrand disease, particularly those unresponsive to desmopressin or undergoing surgery

Design

Review

Authors

GCGiancarlo CastamanAzienda Ospedaliero-Universitaria Careggi

Discussion

Loading...

Member takes

Implication

Supports FVIII/VWF concentrates in severe VWD; leaves open need for randomized confirmation.

Structured PICO

P
Population
Patients with von Willebrand disease (VWD), particularly those unresponsive to desmopressin or undergoing surgery
I
Intervention
FVIII/VWF concentrates (e.g., Haemate P, Alphanate, Fanhdi, Immunate, Wilfactin)

FVIII/VWF concentrates are the treatment of choice for patients with type 3 and type 2B VWD, and severe/intermediate patients unresponsive to desmopressin, effectively preventing and treating bleeding.

Cite This Study

Giancarlo Castaman (2011) studied this question.

synapsesocial.com/papers/6a968d71a45595e5080e2b07https://doi.org/10.2450/2011.003s
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative Analysis and Classification of von Willebrand Factor/Factor VIII Concentrates: Impact on Treatment of Patients with von Willebrand Disease2006 · 73 citations
  2. 2A comparative <i>in vitro</i> evaluation of six von Willebrand factor concentrates2004 · 65 citations
  3. 3The Factor VIII/Von Willebrand Factor Ratio Discriminates between Reduced Synthesis and Increased Clearance of Von Willebrand Factor2002 · 46 citations
  4. 4Factor VIII and von Willebrand Factor1998 · 126 citations
  5. 5Old concepts and new developments in the study of platelet aggregation2000 · 114 citations